Was ESG a stock market vaccine during COVID-19?
Julia Asri Meigh, Head of ESG and Macro Research (New York)
![Post feature](/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaVZIIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--fb94e709ad82908ef11c89f9f015299c3503207c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJY0c1bkJqb0dSVlE2QzNKbGMybDZaVWtpRFRFeU9EQjRPRFV6QmpzR1ZBPT0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--4a0ea5eeb6f0e6d47bff3b653fd69e214040023f/Cover-photo.jpg)
We summarise findings from a recent academic work that investigated whether ESG investing offered funds any resilience during the COVID-19 crisis.
LITERATURE
In this Literature Review, we discuss the August 2020 paper titled